Capnia, Inc.
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
0%
0 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Carbon Monoxide Measurement to Screen for Sickle Cell Disease
Role: collaborator
Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
Role: collaborator
Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
Role: lead
Intranasal CO2 for Allergic Rhinitis
Role: collaborator
The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine
Role: lead
The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis
Role: lead
The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis
Role: lead
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines
Role: lead
The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Seasonal Allergic Rhinitis
Role: lead
Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain
Role: lead
The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis
Role: lead
All 11 trials loaded